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ABSTRACT
The pituitary neuropeptide oxytocin promotes social behavior, and is a potential adjunct
therapy for social deficits in schizophrenia and autism. Oxytocin may mediate pro-social
effects by modulating monoamine release in limbic and cortical areas, which was
investigated herein using in vivo microdialysis, after establishing a dose that did not produce
accompanying sedative or thermoregulatory effects that could concomitantly influence
behavior. The effects of oxytocin (0.03-0.3mg/kg s.c.) on locomotor activity, core body
temperature and social behavior (social interaction and ultrasonic vocalisations) were
examined in adult male Lister-hooded rats, using selective antagonists to determine the role
of oxytocin and vasopressin V1a receptors. Dopamine and serotonin (5-HT) efflux in the
prefrontal cortex (PFC) and nucleus accumbens (NAc) of conscious rats were assessed using
microdialysis. 0.3mg/kg oxytocin modestly reduced activity and caused hypothermia but only
the latter was attenuated by the V1a receptor antagonist, SR49059 (1mg/kg i.p.). Oxytocin at
0.1mg/kg, which did not alter activity and had little effect on temperature, significantly
attenuated phencyclidine (PCP)-induced hyperactivity and increased social interaction
between unfamiliar rats without altering the number or pattern of ultrasonic vocalisations. In
the same rats, oxytocin (0.1 mg/kg) selectively elevated dopamine overflow in the NAc, but
not PFC, without influencing 5-HT efflux. Systemic oxytocin administration attenuated PCP-
induced hyperactivity and increased pro-social behavior without decreasing core body
temperature and selectively enhanced NAc dopamine release, consistent with activation of
mesocorticolimbic circuits regulating associative/reward behavior being involved. This
highlights the therapeutic potential of oxytocin to treat social behavioral deficits seen in
psychiatric disorders such as schizophrenia.
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INTRODUCTION
The cross-species conserved neuropeptide oxytocin is synthesised in the paraventricular and
supraoptic nuclei of the hypothalamus (Neumann et al, 1993) and acts via central and
peripheral oxytocin and vasopressin V1a and V1b receptors, as well as renal V2 receptors
(Borthwick, 2010; Smith et al, 2017). In addition to established roles in lactation and
parturition oxytocin is a key regulator of social and affective behavior (Grinevich et al, 2016;
Meyer-Lindenberg et al, 2011). Accumulating evidence implicates its dysregulation in
several neuropsychiatric disorders (Romano et al, 2015), and oxytocin has received
considerable recent interest as a potential adjunct therapy for the social deficits in
schizophrenia (Bradley and Woolley, 2017; Kirsch, 2015).
Pro-social effects of oxytocin occur across species on multiple facets of interaction, enabling
mechanistic studies in rodents. Acute intracerebral administration increases rat maternal
behavior (Pedersen and Prange, 1979) and contributes to partner preference in monogamous
prairie voles (Insel and Hulihan, 1995), while chronic administration suppresses aggression
(Calcagnoli et al, 2014) and attenuates stress-induced behavior, cardiac and autonomic
changes in rodents (Grippo et al, 2009). The oxytocin-induced decrease in 40kHz ‘distress’
calls by maternally separated rat pups (Insel and Winslow, 1991) was reversed by an
oxytocin antagonist, suggesting involvement of this receptor. However, there are no reports
of the effect of oxytocin on rat 50kHz ultrasonic vocalisations (USVs) accompanying positive
emotional states specific to reward-associated situations which may have translational
relevance to communicative deficits associated with negative symptoms in man (Simola,
2015; Wohr et al, 2008; Wohr and Schwarting, 2013; Wright et al, 2010).
The NMDA receptor antagonist phencyclidine (PCP) can produce ‘schizophrenia-like’
psychotic behavior and cognitive impairments in normal healthy individuals, and reversal of
acute PCP-induced hyperactivity in rodents (associated with enhanced prefrontal cortex
(PFC) and nucleus accumbens (NAc) dopamine and 5-HT release) has been widely used to
assess potential antipsychotic drug activity (Hackler et al, 2010; Jentsch and Roth, 1999; Li et
al, 2010; Millan et al, 1999). The effect of oxytocin on PCP-induced hyperactivity, as
performed herein, has not been reported before.
The formation and maintenance of social bonds in mammals is thought to involve oxytocin-
dopamine interactions in the mesocorticolimbic system (Fernandez et al, 2018; Skuse and
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Gallagher, 2009) and reinforcement of social reward requires oxytocinergic enhancement of
dorsal raphe serotonergic input to the NAc (Dolen et al, 2013). Infusions of oxytocin into the
ventral tegmental area (VTA) of Long Evans rats selected for high grooming behavior,
increased NAc dopamine release during bouts of pup grooming which was attenuated by
VTA-infusion of an oxytocin receptor antagonist (Shahrokh et al, 2010). The localisation of
oxytocin receptors to brain regions associated with reward, including the VTA, NAc and
prelimbic cortex, suggest that bond formation and social attachments may have rewarding
properties (Insel, 1997; Love, 2014; Smith et al, 2017). In addition, partner preference in
female prairie voles is differentially influenced by dopamine receptor subtype activation; D1
receptors inhibit while D2 receptors facilitate partner preference (Aragona et al, 2006;
Gingrich et al, 2000; Liu and Wang, 2003). Furthermore, micro-infusion of oxytocin
increased NAc dopamine overflow (Young et al, 2014) consistent with the proposed
involvement of dopamine/oxytocin interaction on social behavior, although the downstream
mechanisms involved are unclear. Therefore, we also determined the impact of oxytocin on
PFC and NAc dopamine and serotonin (5-hydroxytryptamine 5-HT) release by microdialysis
to evaluate their potential role in mediating the pro-social effects observed.
The blood brain barrier (BBB) penetration of oxytocin is extremely low. A fundamental
unresolved controversy limiting any translational therapeutic potential (Meyer-Lindenberg et
al, 2011) is whether changes in CNS function can be achieved via systemic administration of
the neuropeptide (Leng and Ludwig, 2016) without concomitant adverse peripheral effects,
and the mechanisms underlying such CNS effects are yet to be elucidated. The variable
effects of oxytocin in preclinical paradigms evaluating positive, negative and cognitive
symptoms of schizophrenia (Feifel et al, 2016) may also be due to confounding activation of
other receptors such as the V1a. The doses required for ‘desired’ and side-effects of oxytocin
are species and gender specific, perhaps reflecting species variation in receptor distribution
and sexual dimorphism in innervation (Smith et al, 2017; Uhl-Bronner et al, 2005), and may
also vary by rat strain. As there are no published effects of oxytocin in Lister-hooded rats,
initial dose-response studies established a dose that did not induce hypothermia or
hypolocomotion and used oxytocin and V1a receptor antagonists to elucidated the receptor(s)
responsible for these unwanted peripheral effects before determining the effect of oxytocin on
PCP-induced hyperactivity, social interaction, USVs and monoamine release by
microdialysis.
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MATERIALS AND METHODS
Animals
Fifty six male Lister-hooded rats (150-200 g; Charles River UK) were housed in groups of
four in ventilated cages or, following surgery for microdialysis, in individual cages. Rats
were maintained in a controlled environment (21 ± 2 oC and 55 ± 10 % humidity) on a 12 h
light-dark cycle (lights on 06:00h) with food and water ad libitum. All experiments were
performed in the light phase, and procedures conducted in accordance with the Animals
(Scientific Procedures) Act, 1986, the ARRIVE guidelines (Kilkenny et al, 2010) and
approval of the University of Nottingham Local Ethical Committee. Group sizes were
selected on the basis of our previous publications using these behavioral (Watson et al, 2016)
and microdialysis techniques (Shortall et al, 2016).
Drugs
Oxytocin acetate was purchased from Bachem (Saint Helens, UK), the oxytocin antagonist L-
368,899 hydrochloride ((2S)-2-Amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[[4-(2-methylphenyl)-
1-piperazinyl]sulfonyl]methyl]bicyclo[2.2.1]hept-2-yl]-4-(methylsulfonyl)butanamide) from
Tocris (Bristol, UK), phencyclidine hydrochloride (PCP) and the V1a receptor antagonist
SR49059 ((2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide) relcovaptan,
from Sigma Aldrich (Poole, UK). All compounds were dissolved in 0.154M saline (vehicle
also containing 5% DMSO for the antagonists) and administered at volume of 1 ml/kg s.c.
(oxytocin) or 2 ml/kg i.p. (all other compounds). Doses are expressed as the salt. In all cases
the experimenter was unaware of the treatment received both during administration and
observation.
Dose-response and antagonist studies with oxytocin on core body temperature and
locomotor activity
To establish a suitable dose of oxytocin which would not suppress locomotor activity (LMA)
or produce hypothermia during microdialysis studies, rats (n=12) were tested using a within-
subjects design on four occasions at weekly intervals following injection of vehicle and each
dose of oxytocin (0.03, 0.1 or 0.3 mg/kg s.c.) in a pseudo-random order to serve as their own
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control. This range was selected from previous reports showing that oxytocin doses above
0.3mg/kg s.c. or i.p. suppress spontaneous locomotion in other rat strains (Angioni et al,
2016; Hicks et al, 2014; Klenerova et al, 2009) so we included lower doses to identify those
devoid of this unwanted effect. To establish the relative contribution of oxytocin and
vasopressin V1a receptors to hypothermia produced by the highest dose, a further twelve rats
received vehicle or oxytocin (0.3mg/kg s.c.) in the presence and absence of the non-peptide
selective V1a receptor antagonist SR49059 (1 mg/kg i.p.) or the selective oxytocin antagonist
L-368,899 (2 mg/kg i.p.), on six occasions at weekly intervals (within-subjects design).
Although original peptide antagonists for these receptors showed poor stability and
selectivity the development of non-peptide antagonists greatly improved pharmacokinetic
properties (Manning et al, 2012). The current non-peptide antagonists (SR49059 and L-
368,889) were selected because they possess the best overall profile of commercially
available oxytocin and V1a antagonists; having high affinity, relative selectivity, good BBB
penetration and plasma half-life (Manning et al, 2012) and are devoid of partial agonist
activity. Doses of these brain penetrant antagonists were selected from previous studies
showing <15min onset and 2-4h duration in rodents. SR49059 prevented oxytocin-induced
pro-social behavior (Ramos et al, 2013) and hypothermia (Hicks et al, 2014), while L-
368,899 (which has brain penetration demonstrated by PET studies (Smith et al, 2013)),
prevented anxiolytic effects of oxytocin in the open field (Klenerova et al., 2009), reduced
conditioned disgust behavior during social interaction (Boulet et al, 2016) and attenuated
sexual motivation in male rats (Blitzer et al, 2017). The cross-over repeat within-subject
design for dose response and antagonist studies greatly reduced the number of rats required
and the inter-individual variation of measurements made in line with the 3R’s principle.
Temperature microchips
Temperature microchips (Bio-Thermo idENTICHIP; AnimalCare Ltd; York, UK) were
implanted s.c. 48h before behavioral testing under brief manual restraint, to enable
subsequent temperature recording via a digital chip reader with minimal disturbance to the
animal, at 15min intervals during assessment of LMA.
Locomotor Activity
LMA was recorded as described previously (Watson et al, 2016). Briefly, rats were placed
into individual Perspex boxes (39 x 23.5 x 24.5 cm with removable wire lids) surrounded by
a dual-level photobeam activity system (San Diego instruments, CA, USA). A single
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ambulation count was recorded for every two consecutive adjacent lower beam breaks and
cumulative beam breaks were recorded in 5 min epochs for 2 h. Oxytocin or vehicle were
administered following 30 min arena habituation and in the antagonist study antagonists were
administered 15 min prior to oxytocin.
Effect of oxytocin on PCP-induced hyperactivity, social interaction and PFC and NAc
dopamine and 5-HT efflux
Oxytocin at 0.03 and 0.1mg/kg were selected for further investigation, as these doses did not
produce confounding effects on ambulation and body temperature in dose-response studies
described above. A separate group of rats (n=32, Figure S1) was used to examine the effect of
these two doses on PCP-induced hyperactivity, and on the basis of these findings 0.1mg/kg
oxytocin was administered 7 days later, prior to assessment of social interaction and
ultrasonic vocalisations (USVs). The following week rats underwent stereotaxic surgery to
implant microdialysis probes into the PFC and NAc and after 7 days recovery the effects of
oxytocin on dopamine efflux from these brain regions was assessed. One week was left
between each of the three protocols (Figure S1) to ensure complete drug wash-out and
minimise any carry over effects from the previous procedure.
Locomotor activity
LMA was assessed on a single occasion as described above. Animals received oxytocin or
vehicle after 30 min arena habituation, and vehicle or PCP (5.6 mg/kg i.p.; (Hackler et al,
2010) an established dose to examine ‘antipsychotic-like’ activity) 30 min later, resulting in 4
treatment combinations: vehicle + vehicle, PCP + vehicle, PCP + 0.03mg/kg oxytocin, PCP +
0.1mg/kg (n=8/group; between-subjects design).
Social Interaction
Two rats from different litters matched for weight (<30 g difference) and treatment were
sprayed on the nape with blue or pink hair dye 45 min prior to the trial to facilitate video
tracking. Both rats received 0.1 mg/kg oxytocin or vehicle 45 min before placement into an
unfamiliar circular arena (75cm diameter) under low light conditions (40LUX) for 10 min
(Bull et al, 2003; Watson et al, 2016). Ethovision (Noldus) was used to record interactive
behaviors, including body sniffing, ano-genital sniffing, following, crawling over-and-under,
lying side-by-side, pinning and boxing/biting and to derive total social interaction. As the
behavior of each rat depends on that of the partner, an average time was derived for each pair
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(n=8 per treatment) rather than each rat. Body temperature was recorded by telemetry
immediately before and after social interaction.
Ultrasonic Vocalisations (USVs)
Both 22 kHz (alarm) and 50 kHz (prosocial) USVs were recorded during social interaction as
previously described (Watson et al, 2016). An electret microphone (Emkay, Avisoft
Bioacoustics, Germany) connected to an ultrasound detection unit (Ultrasound Gate,
customised model 112, Avisoft Bioacoustics, Berlin) was secured above the arena. The
resulting signal was digitalised and saved as .wav files. Temporal and frequency
characteristics of 50 kHz calls were extracted using Avisoft analysis software (SAS-Lab Pro,
v 4.38, Avisoft Bioacoustic, Berlin) and categorised offline into flat, step or trill subtype,
according to pattern analysis (Brenes et al, 2016; Simola, 2015). Flat calls had peak
frequency changes ≤5 kHz, although the difference between start and end frequencies could 
be >5 kHz if it had an upward or downward direction. Step calls had at least one short
element >5 kHz higher or lower than the fundamental call. Trill calls had at least one
frequency modulation with a longer element than step calls and/or a common zig-zag pattern
often appearing as inverted-U shapes.
Surgery and microdialysis
One rat from each social interaction pair (n=16 in total) was anaesthetised with isoflurane in
O2 and N2O, placed in a stereotaxic frame and CMA 12 guide cannulae (Linton
Instrumentation; Diss, UK) implanted into the PFC and NAc (AP +3.2, L -0.7, V -2.3 and AP
+1.7, L +1.6, V -3.8 respectively from Bregma; (Paxinos and Watson, 1986)). Guide
cannulae, two copper-wire tethers and stainless steel screws were secured in place with dental
acrylic. Carprofen (1mg/kg s.c.) was administered pre-surgery and lignocaine applied
topically around sutures post-surgery.
One week later, rats were briefly re-anaesthetised to insert microdialysis probes (0.5mm x
4.0mm membrane length with molecular cut-off 20,000 Da; CMA 12, Linton
Instrumentation) into the guide cannulae. Probes were perfused continuously with aCSF
(125mM NaCl, 1.25mM KCl, 0.5mM MgCl2, 13.5mM NaHCO3, 0.2mM NaH2PO4, 0.90mM
Na2HPO4, 0.30mM Na2SO4 and 1.2mM CaCl2) at 1 µl/min using dual-syringe pumps
(Harvard Apparatus; Cambridge, UK). Rats were placed into an arena (50cm diameter, 45cm
height, containing sawdust bedding), with the microdialysis tubing attached to a dual channel
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swivel (Linton Instrumentation) and swivel mounted tether (Linton Instrumentation) allowing
free movement (Shortall et al, 2016). The following day, three baseline samples were
collected (in vials containing 5 µL 0.1M perchloric acid (Fisher Scientific, UK) and 0.03%
sodium metabisulphite (Sigma Aldrich, UK) and kept on dry ice until storage at -80oC) at
20min intervals before and for 2h after injection of either oxytocin 0.1mg/kg s.c. or saline
(1mg/ml). At the end of the study, rats were euthanised with sodium pentobarbital (Euthatal)
i.p. and brains dissected and stored in 4% PFA at 4oC for histological verification of probe
placement.
Analysis of Monoamines
Microdialysis samples were analysed using High Performance Liquid Chromatography with
electrochemical detection (HPLC-ED) as described previously (Shortall et al, 2016).
Defrosted samples were kept on ice before injection (15µl) into a Targa C18 3µM column
(100 x 1.0mm; Higgins Analytical) using a Perkin Elmer Series 200 autosampler (Antec
Leyden, The Netherlands). Dopamine, 5-HT and their major metabolites; 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoleacetic
acid (5-HIAA) were detected using a mobile phase (20mM potassium dihydrogen phosphate,
20mM sodium acetate, 0.1mM ethylenediaminetetraacetic acid (EDTA), 0.15mM
octanesulfonic acid and 10% methanol, pH 3.9) at 0.4ml/min (Dionex P680 pump), and
measured against standards with a DECADE II SDC Detector I (Antec; Leyden, The
Netherlands) and Clarity software (Data Apex) using a potential of +0.75V. The percentage
change from baseline for every microdialysate molecule was calculated for each individual
rat. PFC samples were excluded from one rat due to incorrect probe placement and two others
because of flow disruption. In one rat NAc dopamine was below the detection limit; n=6/7
per group in the PFC, and n=7/8 in the NAc.
Data analysis
All analyses were perfomed by GraphPad Prism v7 (GraphPad Software Inc.) and SPSS
(v24) and data were checked for normality and homogeneity of variance using Shapiro-
Wilk’s and Levene’s tests, respectively. The time course of LMA and body temperature in
studies that employed a within-subject design were analysed using two-way repeated
measures ANOVA (oxytocin dose response study) or three-way repeated measures ANOVA
(antagonist study) with oxytocin, antagonist (where used) and time as factors and total
cumulative activity counts used repeated measures ANOVA. Data from PCP and
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microdialysis studies, which had a between-subject design, were analysed by two-way
ANOVA with treatment as a between subjects factor and time as a repeated measure.
ANOVA’s were followed by Tukey’s or Sidak multiple comparison post hoc tests where
appropriate. Data are presented as mean±SEM and P<0.05 considered significant.
RESULTS
Effect of oxytocin on locomotor activity and body temperature
During LMA rats habituated to the arena such that ambulation progressively decreased (F(23,
1012)=86.20, P<0.0001) over 2h. Dose-response studies (Figure 1A) showed acute oxytocin
(0.03, 0.1 or 0.3 mg/kg) had no effect, such that ANOVA revealed no significant main effect
of treatment (data not shown). There was also no effect of oxytocin on total cumulative
ambulatory activity over 90min (F(3, 44)=1.293, P=0.2888; one-way repeated measures
ANOVA, Figure 1B). Although the cumulative activity counts tended to be reduced by the
highest dose (0.3 mg/kg) this failed to reach significance in this group.
During the LMA task, rat core body temperature modestly decreased (F(7, 308)=31.82,
P<0.0001), but post-injection the highest dose of oxytocin (0.3 mg/kg) produced significantly
greater hypothermia than either saline or the two lower doses of oxytocin (F(3, 44)=23.73,
P<0.0001). There was also a treatment x time interaction (F(21, 308)=14.29 P<0.0001;
ANOVA). Oxytocin at 0.3 mg/kg produced a significantly (P<0.05, 0.01 or 0.001; Tukey
post-hoc) greater decrease in temperature than vehicle between 15-60 min post-injection,
whereas 0.1 mg/kg slightly decreased temperature at the 30 min time point only (Figure 1C).
Role of oxytocin and V1a receptors in oxytocin-induced LMA and hypothermia
Following pretreatment with either a selective oxytocin and V1a receptor antagonist
(according to the protocol shown in Figure 2A) three-way ANOVA of the time course of
LMA counts confirmed main effect of oxytocin (F(1,11)=34.776, P=0.0001) and time
(F(17,187)=15.441, P=0.0001) but no significant effect of antagonist and no significant
oxytocin x antagonist or oxytocin x antagonist x time interactions. Thus for total cumulative
activity counts post-injection, 0.3mg/kg oxytocin produced a modest (and in this group) a
significant reduction in the cumulative locomotor activity counts from that seen in vehicle
controls (P<0.01) which was unaffected by pre-treatment with either L-368,889 or SR49059,
neither of which affected activity on their own (Figure 2B). At the same time similar analysis
of body temperature (Figure 2C) showed main effects of oxytocin (F(1,11)=59.162, P=0.001),
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antagonist (F(2,22)=5.046, P=0.016) and time (F(7,77)=47.072, P=0.0001) and a significant
oxytocin x antagonist x time interaction (F(14,154)=4.156, P=0.0001). Oxytocin produced a
marked (approximately 2oC) reduction in body temperature reaching a peak 30 to 60 min
post-injection which was significantly lower than that in vehicle treated controls (P<0.0001).
The hypothermia induced by oxytocin from 30-60 min post-injection was significantly
attenuated (P<0.05 to P<0.001) by the V1a receptor antagonist, SR49059, such that body
temperature was not significantly different from vehicle at any time point in the SR49059 +
oxytocin group. In contrast, the time course and magnitude of hypothermia produced by
oxytocin was comparable in the absence and presence of the oxytocin receptor antagonist L-
368,889.
Effect of oxytocin on PCP-induced hyperactivity
A separate group of rats received rats was used to consecutively examine the effect of
oxytocin on PCP-induced hyperactivity, social interaction and PFC and NAc dopamine and
5-HT efflux by microdialysis according to the protocol in Figure 3A. The highest dose of
oxytocin attenuated the magnitude of the PCP-induced hyperactivity such that in the 90min
following injection with oxytocin there was a significant main effect of time (F(17, 476)=19.86,
P<0.0001), treatment (F(3, 28)=25.88, P<0.0001) and a treatment x time interaction (F(51,
476)=3.428, P<0.0001; Figure 3B). There was no difference in the magnitude of LMA
response between PCP rats that received pre-treatment with saline or the low dose of
oxytocin. In contrast 0.1 mg/kg oxytocin produced an approximately 50% reduction, such
that LMA was significantly less (P<0.05 or P<0.01) than both saline and low dose oxytocin
groups between 20 and 45min after PCP injection.
As expected the cumulative ambulatory count following injection of PCP was significantly
greater than saline, such that there was a significant main effect of treatment (F(3, 28)=24.34,
P<0.0001; one-way ANOVA). Consistent with the time course data, only the highest dose of
oxytocin (0.1 mg/kg) significantly attenuated PCP-induced hyperactivity compared to
vehicle-PCP treated rats (P<0.01, Tukey post-hoc, Figure 3C), which was still significantly
greater (P<0.01) than the basal activity seen in saline controls.
The body temperature of rats measured during LMA gradually reduced over time (F(7,
189)=20.17, P<0.0001; two-way repeated measures ANOVA) by approximately 0.5oC.
However, there was no significant effect of oxytocin at either dose on the magnitude (F(3,
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27)=1.325, P=0.2868) or time course of the temperature change (treatment x time interaction
F(21, 189)=0.6389, P=0.8860; Figure 3D).
Effect of oxytocin on social interaction
Socially interactive behaviors including ano-genital sniffing, body sniffing, crawling over-
and-under, following, pinning, lying side-by-side, as well as aggressive boxing/biting
behavior were scored manually post-trial. Both the total time spent undergoing pro-social
behavior and engaged in each individual behavioral component was similar to that previously
reported by us in group-housed control rats (Watson et al, 2016). Comparison of vehicle and
oxytocin-treated rats revealed significant main effects of both treatment (F(1, 98)=7.001,
P=0.0095) and behavioral component scored (F(6, 98)=123, P<0.0001) and a treatment x
behavior interaction (F(6, 98)=3.241, P=0.006). Rats given oxytocin (0.1mg/kg) engaged in
significantly more body sniffing (P<0.05) and ano-genital sniffing (P<0.001; Sidak post-hoc)
compared to saline controls (Figure 4A) but there were no differences in any of the other five
behavioral components.
Oxytocin also significantly increased the total time spent in social interaction (mean±SEM =
71.6±4.3s), compared to those receiving vehicle (56.9±4.1s; P<0.05 unpaired Student’s t-test;
Figure 4B).
Comparison of temperature change from baseline, before and after social interaction showed
that core body temperature increased during the trial (F(2, 60)=23.3, P<0.0001). Oxytocin
reduced the extent of hyperthermia (F(1, 30)=5.011, P=0.0328) such that there was a treatment
x time interaction (F(2, 60)=2.41, P=0.0985). The temperature difference between vehicle and
oxytocin-treated rats was close to significance before (P=0.0954) but reached significance
(P=<0.05; Sidak test; Figure 4C) immediately after the social interaction trial.
Effect of oxytocin on USVs
Pro-social 50 kHz USVs emitted from each rat pair during social interaction was quantified
according to three defined subtypes; flat, step and trill (Brudzynski, 2015) following Fast
Fourier transformation and pattern analysis (Figure 4E). A two-way ANOVA of USVs
following a log10 transformation (to normalise data), revealed a significant main effect of the
call type (F(2, 42)=18.75, P<0.0001) emitted (flat being more frequent than step or trill) but this
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was unaltered by oxytocin treatment (F(1, 42)=0.8109, P=0.3730; Figure 4D). No rats emitted
any 22 kHz USVs, so no analysis could be performed on these calls.
Effect of oxytocin on PFC and NAc dopamine and 5-HT efflux
Pre-injection basal dopamine and 5-HT levels (average of initial triplicates) were determined
in the PFC and NAc and used to calculate the percentage change for each monoamine.
Compared to initial basal dopamine levels (0.0728 and 0.176 pmol/ml in the PFC and NAc,
respectively) oxytocin (0.1mg/kg) produced a significant (F(1, 12)=7.983, P=0.0153) persistent
(approximately 100%) elevation of overflow in the NAc, but the much more varied trend to
increase DA in the PFC did not reach significance (F(1, 11)=4.254, P=0.0634; Figure 5A). In
order to ascertain if the effect on cortical dopamine could be more transient than the NAc
analysis was also performed on the data in the first 60 and 80 min post-injection but this was
also not significant. There was no significant effect of time nor any treatment x time
interaction (p>0.05) in either brain region.
In contrast, basal 5-HT levels (PFC and NAc being 2.212 and 3.677 pmol/ml, respectively)
were unaltered by oxytocin injection such that there was no significant main effect of
treatment or time nor any treatment x time interaction in either the PFC (F(1, 11)=0.06091,
P=0.8096) or NAc (F(1, 14)=0.08213, P=0.7786; Figure 5B). Microdialysate levels of the
major metabolites of DA and 5-HT (DOPAC, HVA and 5-HIAA) were also unaltered from
basal levels by oxytocin or vehicle and remained stable across time post-injection (Figure
S2). As extracellular levels of DOPAC, HVA and 5-HIAA reflect intracellular metabolism of
their respective neurotransmitter, microdialysate levels of these metabolites would not be
expected to mirror nor provide an index of corresponding neurotransmitter release.
Core body temperature slowly and progressively decreased over 2h post-injection (F(8,
104)=11.05, P<0.0001) and although there was no main effect of treatment (F(1, 13)=3.129,
P=0.1003), there was a significant time x treatment interaction (F(8, 104)=2.482, P=0.0167;
two-way repeated measures ANOVA). Oxytocin only caused significantly greater
hypothermia than vehicle at 45min post-injection (P<0.05; Sidak post-hoc; Figure 5C).
DISCUSSION
This study demonstrates the ability to dose differentiate the effect of systemic oxytocin
injection on reversal of PCP-induced LMA and pro-social behavior from hypothermia and
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‘sedative-like’ hypoactivity in Lister-hooded rats. Importantly oxytocin enhanced social
interaction without simultaneously altering 50 kHz pro-social calls, suggesting that this
behavior resulted from direct neuronal modulation by oxytocin. Accompanying microdialysis
data suggests this may be mediated, at least in part, by selective enhancement of dopamine
(and not serotonin) release preferentially in the NAc, and not the PFC, from
mesocorticolimbic circuits involved in associative/reward behavior.
Although as little as 0.01% of systemic oxytocin may reach the rat CNS because of poor
penetration of the BBB (Meyer-Lindenberg et al, 2011; Striepens et al, 2013) and the
estimated blood half-life is ~5min, the cerebrospinal fluid half-life is considerably longer (at
least 20min (Ludwig and Leng, 2006)) and could provide a compartment for more sustained
CNS actions (Leng and Ludwig, 2016) similar to those reported herein. Several previous
studies show intranasal and intracerebral oxytocin administration enhances rodent social
behavior (Calcagnoli et al, 2015; Insel and Winslow, 1991; Lukas et al, 2011; Witt et al,
1992) which may also occur in humans (Gibson et al, 2014; Kosfeld et al, 2005; Shin et al,
2015). As the rat pituitary contains ~1g oxytocin, even minimal brain penetration of
supraphysiological amounts given systemically could alter brain function, since as little as
1ng intracerebroventricular oxytocin produces behavioral effects in rodents (Arletti and
Bertolini, 1985). In addition, exogenous oxytocin may activate peripheral afferents or
subfornical organ projections to the paraventricular nucleus (Iovino et al, 2016) as well as
acting directly on magnocellular neurons, all of which may enhance endogenous oxytocin
release by positive feedback (Falke, 1989) resulting in diffuse dendritic release (Ludwig and
Leng, 2006) and a prolonged effect. Consistent with this proposal fMRI BOLD in rats has
suggested systemic oxytocin does not activate the same receptor rich areas as
intracerebroventicular administration (Ferris et al, 2015) and following subcutaneous
injection oxytocin levels double in amygdala and hippocampal microdialysates for 30-60 min
(Neumann et al, 2013). The current study shows robust changes in behavior and increased
NAc dopamine release following subcutaneous oxytocin injection in Lister-hooded rats
during a similar time period.
Dose-response studies established that 0.3mg/kg s.c. oxytocin produced hypothermia in
Lister-hooded rats (-2oC, peaking at 30-60 min post-injection) and even this high dose caused
limited suppression of activity; causing a significant reduction cumulative LMA over 90 min
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post-injection in one of the two groups examined. By comparison, lower doses (0.03 or 0.1
mg/kg) of oxytocin produced little hypothermia and no effect on LMA. Thus the current
observation that ~0.3mg/kg s.c. oxytocin is at the threshold where attenuation of locomotor
activity reaches significance in Lister hooded rats is consistent with findings by Hicks et al
(2014) and Klenerova et al (2009) in Wistar, and Angioni et al (2016) in Sprague-Dawley
rats, where hypoactivity only occurred with 1 or 2 mg/kg i.p. oxytocin. Similarly, in behavior
and microdialysis studies herein, 0.1mg/kg oxytocin had no effect on activity and caused a
very small (0.2oC) decrease in body temperature. Of particular note the hypothermia recorded
with the highest dose of oxytocin (0.3 mg/kg) in this study was markedly attenuated by the
selective V1a receptor antagonist SR49059 but unaffected by the oxytocin antagonist L-
368,899 which is brain penetrant (Boccia et al, 2007) and attenuates oxytocin-induced
hypoactivity in Wistar rats at the dose used in this study (Klenerova et al, 2009). Previous
biotelemetry studies (Hicks et al, 2014) also suggest the thermoregulatory effects of systemic
oxytocin primarily involve V1a receptor activation and support the proposal that the pro-
social and microdialysis effects reported in this study (with lower doses that cause little
hypothermia) may be mediated primarily by oxytocin receptor and not V1a receptor
activation. In accord with a previous report in Wistar rats (Klenerova et al, 2009) the
‘sedative-like’ hypoactivity seen with the highest dose of oxytocin was only partially
attenuated SR49059 or L-368,889. Therefore this hypoactivity could be mediated by oxytocin
acting at distinct receptors, potentially the V1b (located in the pituitary in adults) for which it
has modest affinity, or allosteric modulation of dopamine binding at oxytocin-D2 dopamine
receptor heterodimers (Romero-Fernandez et al, 2013), if these exist in vivo. In contrast, in
Sprague-Dawley rats LMA suppression produced by 2 mg/kg i.p. oxytocin was mimicked by
microinjection into the substantia nigra and prevented by intracerebroventricular injection of
an oxytocin antagonist, and therefore could result from activation of oxytocin receptors on
nigrostriatal dopaminergic neurons (Angioni et al, 2016).
At 0.1 mg/kg oxytocin markedly attenuated PCP-induced hyperactivity, whilst the low dose
(0.03 mg/kg) had no effect. No previous study has examined the effect of oxytocin on
NMDA antagonist-induced hyperactivity, but notably oxytocin (2 mg/kg i.p.) decreased
methamphetamine-induced hyperactivity in rats (Carson et al, 2010a) accompanied by
attenuation of induced Fos protein expression in the subthalamic nucleus and NAc core
(Carson et al, 2010b), suggesting these regions may be involved. Furthermore, oxytocin also
attenuated cocaine-induced hyperactivity and the concomitant reduction in post-mortem NAc
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dopamine content in mice (Kovacs et al, 1990). Both PCP and methamphetamine
significantly increased ambulatory activity, and PFC and NAc microdialysate dopamine and
5-HT levels in rodents following acute injection (Li et al, 2010; Millan et al, 1999).
Furthermore, dopamine release measured by chronoamperometry was enhanced by oxytocin
infusion into the NAc and VTA (Love, 2014; Shahrokh et al, 2010), suggesting that oxytocin
can activate mesolimbic dopaminergic neurons. As both PCP and oxytocin enhance NAc
dopamine release it appears paradoxical that this could explain oxytocin attenuation of PCP-
induced LMA. However, when given in combination, oxytocin reduces the
methamphetamine increase in NAc dopamine turnover in mice (Qi et al, 2008). Compared
with amphetamine, PCP more markedly elevates NAc microdialysate 5-HT and PCP-induced
LMA is attenuated by 5-HT2A receptor antagonists (Millan et al, 1999). However, as oxytocin
did not alter NAc or PFC 5-HT release in the current study it is unlikely that direct
modulation of serotonergic function contributes to the attenuation of PCP-LMA observed.
Although a small decrease (0.2-0.4oC) in body temperature was seen 30 to 45min after
0.1mg/kg oxytocin administration in the current dose-response and microdialysis studies, this
is unlikely to account for the selective elevation in NAc DA overflow observed since
hypothermia (Brannan et al, 1992) reduces striatal DA levels in microdialysates. Acute PCP
activates PFC glutamatergic efferents to the VTA which also contribute to the motoric
enhancement observed (Takahata and Moghaddam, 2003). The locomotor hyperactivity and
elevation in microdialysate dopamine efflux in the NAc are both attenuated by injection of
the dopamine receptor antagonist flupenthixol into the NAc (Del Arco et al, 2008), consistent
with corticolimbic pathways contributing to PCP hyperactivity. Furthermore, oxytocin
attenuates the medial PFC methamphetamine-induced increase in glutamate in an oxytocin
receptor sensitive manner (Qi et al, 2012). So far no studies have examined whether a similar
interaction occurs with PCP. Oxytocin-induced facilitation of mesolimbic dopaminergic
function and accompanying facilitation of NAc dopamine release have been shown to
regulate maternal behavior and chemical lesions or microinjection of dopamine antagonists
disrupt this (Insel, 1997; Love, 2014; Shahrokh et al, 2010). Oxytocin containing
parvocellular neurons of the paraventricular nucleus project to the NAc and VTA, while
oxytocin neurons of the medial preoptic area innervate the VTA whose dopamine neurons in
turn innervate the NAc and the PFC (Love, 2014). Both the VTA and NAc have oxytocin
receptors, which would be targets of peripheral administration or brain penetrant drugs (Love,
2014; Smith et al, 2017). By using oxytocin receptor Cre mice (Peris et al, 2017) it has been
shown that glutamatergic neurons in the VTA also express oxytocin receptors and oxytocin
Kohli et al. Oxytocin enhances social behavior and accumbens dopamine
17
likely also modulates glutamatergic neuronal function, as oxytocin receptor knockout mice
show larger deficits in sensorimotor gating following PCP than wildtype mice (Caldwell et
al, 2009). Thus glutamatergic modulation by oxytocin might also contribute to attenuate
PCP-induced LMA.
Activation of oxytocinergic neurons in the PVN and supraoptic hypothalamic nuclei (which
express 5-HT1A receptors (Uvnas-Moberg et al, 1996)) by input from dorsal raphe 5-HT
neurons promotes oxytocin release from their terminals in the NAc serving to enhance social
reinforcement (Arakawa, 2017; Emiliano et al, 2007; Fernandez et al, 2018). In addition,
oxytocin heteroreceptors enhances 5-HT release from raphe nerve terminals in the NAc,
reinforcing the rewarding property of social interaction in mice (Dolen et al, 2013). While
NAc DA may signal acute reward reinforcement serotonergic neuronal activation in the NAc
may contribute to delayed gratification reward and social attachment (Fernandez et al, 2018).
Consistent with the current microdialysis observations oxytocin may have little impact on
basal 5-HT release but only enhance NAc 5-HT during social reinforcement. Consistent with
this proposal the oxytocin antagonist, tocinoic acid, does little to social interaction when
given alone but attenuates the facilitation of interaction produced by MDMA or the 5-HT1A
agonist 8-OHDPAT (Thompson et al, 2007).
In this study, oxytocin (0.1 mg/kg) increased pro-social interaction most notably due to
increased ano-genital and body sniffing. Rodents are thought to sniff ano-genital regions of
conspecifics as part of social recognition to decode identity, and an increase might reflect
altered acceptance of familiarity of strangers and facilitate social reciprocity. Similar
enhancement of total pro-social behavior has previously been observed in both mice and rats
(Bowen et al, 2011; Calcagnoli et al, 2014; Huang et al, 2014; Lee et al, 2005; Ramos et al,
2013) following oxytocin administration. The only previous report of peripheral oxytocin
(0.5 mg/kg i.p. in Long Evans rats) on social interaction found increased lying side-by-side
and reduced ano-genital sniffing, both prevented by the V1a receptor antagonist, SR49059,
but not by the oxytocin antagonist, C25 (Ramos et al, 2013). Several groups have shown a
range of doses of both oxytocin and vasopressin produce similar pro-social behavior during
social interaction, also implicating V1a receptors or downstream signalling crosstalk between
oxytocin and V1a receptors in these effects in rats and hamsters (Ramos et al, 2013; Song et
al, 2014; Suraev et al, 2014). The precise brain regions involved in the pro-social effect is
unclear but both peripheral and microinjection of the oxytocin antagonist L-368,899 into the
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NAc reduced social preference in adult male mice in a social reward paradigm (Dolen et al,
2013). By using viral vectors it has been shown that social interaction enhances activity of
PVN oxytocin neurons innervating VTA neurons projecting to the NAc which can be
attenuated by an oxytocin receptor antagonist (Hung et al, 2017) suggesting oxytocin
receptors are also involved. The potential sites of interaction of oxytocin with circuits
connecting the NAc via activation of oxytocin and/or V1a receptors and consequential
alterations in dopamine, GABA, and glutamate are elegantly discussed in a recent review
(Baracz and Cornish, 2016) and further evaluation such as by microinjection with selective
antagonists or lesions using the neurotoxin, saporin-oxytocin, would help delineate the brain
region/s and receptor/s involved.
In contrast to effects on social behavior, oxytocin did not concomitantly alter the number or
pattern of high frequency USVs consistent with a previous report that arginine-vasopressin
failed to alter 50 kHz USVs in rats (Lukas and Wohr, 2015). 50 kHz USVs are emitted in
positive behavioural or rewarding situations (including social play and sexual behavior), and
thought to reflect positive affective state (Brudzynski, 2015), and if played back to rats
induce approach behavior (Seffer et al, 2015). Furthermore 50 kHz USVs are attenuated by
dopamine D1 and D2 antagonists and 6-hydroxydopamine lesion of the VTA dopamine
neurons (Burgdorf et al, 2007). Since USVs were unaltered by oxytocin herein the change in
social behavior between rat pairs probably results from activation of mesocorticolimbic
circuits (Wohr and Schwarting, 2013) and is not driven by altered communicative calls.
Despite evidence that high doses of oxytocin cause receptor internalisation (Huang et al,
2014; Klein et al, 2011), repeated low dose oxytocin exposure causes enduring increases in
social interaction in rats (Suraev et al, 2014), potentially resulting from synaptic plasticity
enhancing the serotonergic input to the NAc, reinforcing the rewarding impact of social
behavior (Dolen et al, 2013). The extent of BBB penetration following intranasal oxytocin
administration in man is controversial (Leng and Ludwig, 2016). This study in rats show that
peripheral oxytocin administration can enhance social interaction and increase NAc
dopamine overflow, without producing accompanying sedative or thermoregulatory effects,
warranting further investigation as a potential therapy for antecedent social behavioral
deficits such as seen in ASD and schizophrenia.
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FIGURE LEGENDS
Figure 1 Effect of oxytocin (OXY, 0.03, 0.1 and 0.3mg/kg; s.c., administered after arena
habituation) or vehicle (VEH, 0.154M saline 1ml/kg) administered according to the protocol
shown in A on four occasions at 7 day intervals so that each rat received every dose on B;
total locomotor activity (LMA, cumulative ambulatory counts, mean±SEM) and C; change in
body temperature (from basal recorded 5 min pre-injection, mean±SEM, oC) in adult Lister
hooded rats (n=12, within-subjects design) recorded in an activity box for 90 min post-
injection. C: *P<0.05, ***P<0.001 VEH vs. 0.3 or 0.1mg/kg OXY; ##P<0.01, ###P<0.001
0.3mg/kg OXY vs. 0.1mg/kg OXY; ++P<0.01 0.3mg/kg OXY from 0.03mg/kg OXY;
Tukey’s post-hoc test.
Figure 2 Determination of the effect of pre-treatment with the selective V1a receptor
antagonist, SR49059 (1mg/kg), or the selective oxytocin receptor antagonist, L-368,899
(2mg/kg), according to the experimental protocol shown in A on B; the cumulative locomotor
ambulatory counts and C; the change in body temperature (oC) over 90 min following
injection of oxytocin (OXY, 0.3mg/kg. s.c., administered 15 min after the antagonist) or
vehicle (VEH, 1ml/kg saline). Data are presented as mean±SEM, n=12 per treatment (within-
subjects design). In B **P<0.01 from VEH + VEH controls. In C * P<0.05 and *** P<0.001
from VEH + VEH controls, + P<0.05, ++ P<0.01 and +++ P<0.001 0.03mg/kg OXY from
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0.3mg/kg OXY and ###P<0.001 0.1mg/kg OXY from 0.3mg/kg OXY, following Tukey’s
post-hoc test.
Figure 3 A; Experimental protocol used to consecutively examine the effect of oxytocin on
phencyclidine-induced behavior (this figure), social interaction (Figure 4) and prefrontal
cortex and nucleus accumbens dopamine and 5-HT efflux by microdialysis (Figure 5), for full
details of the methods see Figure S1. Comparative effect of oxytocin (OXY, 0.03-0.1mg/kg;
s.c) and vehicle (VEH, 0.154M saline 1ml/kg) on (mean±SEM) the B; time course of
phencyclidine (PCP, 5.6mg/kg; i.p.)-induced locomotor activity (LMA; cumulative
counts/5min epoch), C; total ambulatory counts in 1 h (following injection with PCP/VEH),
and D; change in body temperature (from basal, 5min prior to injection, oC) in adult Lister
hooded rats recorded in an activity box. In B and C: *P<0.05, **P<0.01, ***P<0.001
compared to VEH-SAL; +P<0.05, ++P<0.01 compared to VEH-PCP; #P<0.05, ##P<0.01
compared to 0.03mg/kg OXY-PCP; Tukey post-hoc) VEH=saline vehicle, OXY=oxytocin;
n=8 per group (between-subjects design) as indicated VEH-VEH; VEH-PCP; OXY
0.03mg/kg-PCP; OXY 0.1mg/kg-PCP.
Figure 4 Effect of oxytocin (OXY, 0.1mg/kg; s.c.) and vehicle (VEH, 0.154M saline 1ml/kg)
on social interaction between two male Lister hooded rats from different litters paired by
similar weight and the same previous drug treatment, recorded over 10 min. A; individual
behaviors (s), B; total time in social interaction (s), C; body temperature change from basal
(immediately prior to injection), before (45 min post-injection) and after the interaction trial
(55 min post-injection as indicated; oC) and D; the number of pro-social 50 kHz ultrasonic
vocalisations (USVs) emitted by both rats in each pair. All data are presented as mean±SEM.
E; Representative spectrographs showing pro-social 50 kHz USVs emitted from rat pairs
defined into three subtypes; flat, step and trill, following Fast Fourier transformation and
pattern analysis. A; *p=0.05; Student’s unpaired t-test. C; *P<0.05 from OXY. D; Following
log10 transformation, *P<0.05 ***P<0.001 VEH vs. OXY; Sidak post-hoc; VEH=saline
vehicle, OXY=0.1mg/kg oxytocin; n=8 pairs/group. NB. A different time scale is used to
show ano-genital and body sniffing from other, less frequent, behaviors.
Figure 5 Comparison of the effects of oxytocin (OXY, 0.1mg/kg; s.c.) or vehicle (VEH,
0.154M saline 1ml/kg) on A; dopamine and B; serotonin (5-HT) overflow (mean±SEM,
pmol/ml) in the prefrontal cortex (PFC) and nucleus accumbens (NAc) measured by
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microdialysis, and concomitant C; core body temperature (mean±SEM; oC) in freely-moving
rats. A; Changes to dopamine from baseline in the PFC (0.0728 pmol/ml) and NAc (0.176
pmol/ml) over the 2h period. B; Changes in 5-HT levels from baseline in the PFC (2.212
pmol/ml) and NAc (3.677 pmol/ml). PFC: Dopamine: n=7 VEH, n=6 OXY, 5-HT: n=7 VEH,
n=6 OXY; NAc: Dopamine: n=7 VEH, n=7 OXY, 5-HT: n=8 VEH, n=8 OXY; VEH=saline
vehicle, OXY=0.1mg/kg oxytocin; PFC; Prefrontal Cortex, NAc; Nucleus Accumbens. C;
*P<0.05 VEH vs OXY; Sidak post hoc. VEH=saline vehicle, OXY=0.1mg/kg oxytocin; n=8
per treatment group; between-subjects design.
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